Background Meningococcal disease continues to be a global public health concern due to
its epidemic potential, severity, and sequelae. The global epidemiological data on …

Epidemiology of community-acquired bacterial meningitis : Current Opinion in Infectious
Diseases Epidemiology of community-acquired bacterial meningitis : Current Opinion in …

Summary Background Pneumococcal conjugate vaccines (PCVs) that are ten-valent
(PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global …

Abstract Background The World Health Organization (WHO) coordinates the Global Invasive
Bacterial Vaccine-Preventable Diseases (IB-VPD) Surveillance Network to support vaccine …

Background A novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac])
was developed as part of efforts to prevent frequent meningitis outbreaks in the African …

The use of pneumococcal conjugate vaccine (PCV) schedules with fewer doses are being
considered to reduce costs and improve access, particularly in low-and middle-income …

Streptococcus pneumoniae (S. pneumoniae, pneumococcus) is a major cause of morbidity
and mortality worldwide. Achieving long-term immunity against S. pneumoniae through …

Abstract In sub-Saharan Africa, bacterial meningitis remains a significant public health
problem, especially in the countries of the meningitis belt, where Neisseria meningitidis …

Abstract Background In 2013, Burkina Faso introduced 13-valent pneumococcal conjugate
vaccine (PCV13) into the routine childhood immunization program, to be administered to …

Streptococcus pneumoniae's polysaccharide capsule is an important virulence factor;
vaccine-induced immunity to specific capsular polysaccharide effectively prevents disease …